Literature DB >> 16007238

Piracetam: a review of pharmacological properties and clinical uses.

Bengt Winblad1.   

Abstract

Piracetam, a derivative of the neurotransmitter gamma-aminobutyric acid (GABA), has a variety of physiological effects that may result, at least in part, from the restoration of cell membrane fluidity. At a neuronal level, piracetam modulates neurotransmission in a range of transmitter systems (including cholinergic and glutamatergic), has neuroprotective and anticonvulsant properties, and improves neuroplasticity. At a vascular level, it appears to reduce erythrocyte adhesion to vascular endothelium, hinder vasospasm, and facilitate microcirculation. This diverse range of physiological effects is consistent with its use in a range of clinical indications. Its efficacy is documented in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia. While high doses are sometimes necessary, piracetam is well tolerated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007238      PMCID: PMC6741724          DOI: 10.1111/j.1527-3458.2005.tb00268.x

Source DB:  PubMed          Journal:  CNS Drug Rev        ISSN: 1080-563X


  49 in total

Review 1.  Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Authors:  Vladimir Lerner; Chanoch Miodownik
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

Review 2.  Clinical trials in mild cognitive impairment: lessons for the future.

Authors:  V Jelic; M Kivipelto; B Winblad
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

Review 3.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 4.  Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders.

Authors:  Greg C Carlson
Journal:  Pharmacol Biochem Behav       Date:  2011-02-16       Impact factor: 3.533

5.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

6.  Cerebrotendinous xanthomatosis: the effectiveness of high-dose piracetam for the treatment of cerebellar and sensorial ataxia.

Authors:  Ugur Uygunoglu; Aysegul Gunduz; Sukriye F Menku; Basak Yilmaz; Esra Hatipoglu; Cengiz Yalcinkaya; Sabahattin Saip; Hulya Apaydin
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

Review 7.  Molecular basis of pharmacotherapies for cognition in Down syndrome.

Authors:  Katheleen J Gardiner
Journal:  Trends Pharmacol Sci       Date:  2009-12-04       Impact factor: 14.819

8.  Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.

Authors:  Kristina Leuner; Christopher Kurz; Giorgio Guidetti; Jean-Marc Orgogozo; Walter E Müller
Journal:  Front Neurosci       Date:  2010-09-07       Impact factor: 4.677

Review 9.  Alternative medicine and Alzheimer disease.

Authors:  Brendan J Kelley; David S Knopman
Journal:  Neurologist       Date:  2008-09       Impact factor: 1.398

10.  Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5'-nucleotidase and adenosine deaminase activities.

Authors:  Patricia C Marisco; Fabiano B Carvalho; Michelle M Rosa; Bruna A Girardi; Jessié M Gutierres; Jeandre A S Jaques; Ana P S Salla; Víctor C Pimentel; Maria Rosa C Schetinger; Daniela B R Leal; Carlos F Mello; Maribel A Rubin
Journal:  Neurochem Res       Date:  2013-05-16       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.